{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:30:20Z","timestamp":1792783820320,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"European Union Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford NIHR Biomedical Research Centre"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.coi.2016.05.014","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T21:57:28Z","timestamp":1465336648000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"special_numbering":"C","title":["Viral vectors as vaccine platforms: from immunogenicity to impact"],"prefix":"10.1016","volume":"41","author":[{"given":"Katie J","family":"Ewer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S","family":"Rollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian VS","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2016.05.014_bib0310","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0315","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0264-410X(02)00771-5","article-title":"Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers","volume":"21","author":"Moorthy","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_bib0320","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2019Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2016.05.014_bib0325","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2016.05.014_sbref0330","doi-asserted-by":"crossref","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime\u2013boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0335","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0340","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0345","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0350","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0048322","article-title":"A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0360","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0365","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/S0950268805003936","article-title":"Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy","volume":"133","author":"Iob","year":"2005","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.coi.2016.05.014_bib0370","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0000707","article-title":"Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"2","author":"Bejon","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0380","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2016.05.014_bib0385","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2016.05.014_bib0390","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2008.09.084","article-title":"Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy","volume":"26","author":"Greenough","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_bib0395","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_sbref0400","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2016.05.014_bib0405","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe\u2014preliminary report","author":"Agnandji","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0410","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0415","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2016.05.014_bib0420","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2016.05.014_sbref0425","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0430","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0435","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2016.05.014_bib0440","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2016.05.014_sbref0445","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.celrep.2015.10.034","article-title":"Adenoviral vector vaccination induces a conserved program of CD8+ T cell memory differentiation in mouse and man","volume":"13","author":"Bolinger","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2016.05.014_bib0450","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2016.05.014_bib0455","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coi.2016.05.014_bib0460","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2016.05.014_sbref0465","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E","volume":"351","author":"Hansen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2016.05.014_bib0470","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine\u2014preliminary report","author":"Rampling","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0475","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0480","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2016.05.014_bib0485","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coi.2016.05.014_bib0490","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0495","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coi.2016.05.014_bib0505","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/mt.2015.55","article-title":"AAV's Golden Jubilee","volume":"23","author":"Muzyczka","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0510","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0055435","article-title":"Vaccination to conserved influenza antigens in mice using a novel simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus","volume":"8","author":"Vitelli","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0520","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","article-title":"New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation","volume":"27","author":"Lohr","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_bib0525","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV non-structural antigen to MHC Class II associated invariant chain enhances T cell responses induced by vectored vaccines in non-human primates","volume":"22","author":"Capone","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0530","doi-asserted-by":"crossref","first-page":"e100538","DOI":"10.1371\/journal.pone.0100538","article-title":"Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain","volume":"9","author":"Spencer","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0535","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4161\/hv.28974","article-title":"Enhancing poxvirus vectors vaccine immunogenicity","volume":"10","author":"Garc\u00eda-Arriaza","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coi.2016.05.014_sbref0540","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2015.11.028","article-title":"Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter","volume":"34","author":"Alharbi","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_bib0545","doi-asserted-by":"crossref","first-page":"e67888","DOI":"10.1371\/journal.pone.0067888","article-title":"Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice","volume":"8","author":"Pearson","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0550","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1038\/srep05903","article-title":"Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors","volume":"4","author":"Ghobadloo","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2016.05.014_bib0555","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0560","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.coi.2016.05.014_bib0570","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2016.05.014_bib0575","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","author":"Sheehy","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0580","doi-asserted-by":"crossref","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","article-title":"A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS","volume":"9","author":"de Barra","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0585","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2016.05.014_bib0590","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/mt.2014.157","article-title":"Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial","volume":"22","author":"Hodgson","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2016.05.014_bib0595","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2016.05.014_bib0600","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine\u2014preliminary report","author":"Regules","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0605","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","author":"Ledgerwood","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2016.05.014_bib0610","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791516300541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791516300541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:37:53Z","timestamp":1760603873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791516300541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":61,"alternative-id":["S0952791516300541"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2016.05.014","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vectors as vaccine platforms: from immunogenicity to impact","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2016.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}